Plk1-targeted therapies in TP53- or RAS-mutated cancer

克拉斯 PLK1 Polo样激酶 癌症研究 癌症 激酶 胞质分裂 有丝分裂 靶向治疗 医学 生物 遗传学 细胞 结直肠癌 细胞分裂 细胞周期
作者
Hyungshin Yim,Raymond L. Erikson
出处
期刊:Mutation Research-reviews in Mutation Research [Elsevier]
卷期号:761: 31-39 被引量:38
标识
DOI:10.1016/j.mrrev.2014.02.005
摘要

Despite advances in treatment, prognosis for many types of carcinoma remains poor. Polo-like kinase 1 (Plk1) has been explored as a target for the development of anticancer drugs. As a mitotic master Ser/Thr kinase, Plk1 is involved in centrosomal maturation, microtubule nucleation, chromosomal segregation, and cytokinesis. Additional functions in interphase and in response to DNA damage have been revealed. The multiple locations of Plk1 correspond to distinct functions, mediated by phosphorylation of multiple substrates. Since it is highly expressed in several carcinomas, and expression of Plk1 is inversely correlated with the survival rate of patients in non-small cell lung, head and neck, and esophageal cancer, Plk1 is recognized as a valid prognostic marker. Connections between Plk1 and p53 or KRAS in carcinoma provide a rationale and several possible routes to the development of therapies. Tumors with both p53-deficiency and high Plk1 expression may be particularly sensitive to Plk1 inhibitors, although some controversial data exist. In KRAS-mutant cancers, on the other hand, Plk1 may be essential for tumor cell survival, but detailed studies as to whether Plk1 inhibitors are more effective in KRAS-mutant cancers must be performed in order to determine whether this is the case. Here, we present evidence for Plk1 as a prognostic marker and potentially effective target for the treatment of patients with carcinoma, to demonstrate the value of Plk1 as a target for the development of cancer treatment, especially for patients with solid tumors. In addition, the effects of Plk1 inhibition in p53- or KRAS-mutated cancer are discussed with respect to clinical implications. Structural specifics of Plk1 are presented, as well as current strategies for discovering new Plk1 inhibitors by targeting the conserved ATP binding site or polo-box domain of Plk1, in order to develop Plk1-specific anticancer drugs.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
3秒前
3秒前
康桥完成签到,获得积分10
4秒前
桐桐应助闹闹采纳,获得10
5秒前
大个应助小吴同学来啦采纳,获得10
5秒前
镜子应助喻诗云采纳,获得10
6秒前
7秒前
pear发布了新的文献求助10
8秒前
aduo发布了新的文献求助10
8秒前
Ava应助zhuhan采纳,获得10
8秒前
慕青应助TqcPisces采纳,获得10
8秒前
卡皮巴拉发布了新的文献求助10
10秒前
10秒前
优雅的猪完成签到,获得积分10
10秒前
8R60d8应助研友_nv4M28采纳,获得10
13秒前
杨小杨应助科研通管家采纳,获得10
14秒前
Frank应助科研通管家采纳,获得30
14秒前
14秒前
共享精神应助科研通管家采纳,获得10
14秒前
毛豆爸爸应助科研通管家采纳,获得10
14秒前
14秒前
16秒前
淘宝叮咚完成签到,获得积分10
17秒前
doo完成签到,获得积分10
18秒前
弈迩栅完成签到 ,获得积分10
19秒前
20秒前
moon完成签到,获得积分10
20秒前
橙色小瓶子完成签到,获得积分10
21秒前
21秒前
脑洞疼应助passion采纳,获得30
22秒前
我是老大应助Edna采纳,获得50
23秒前
23秒前
23秒前
Hello应助Mircale采纳,获得10
23秒前
TqcPisces发布了新的文献求助10
24秒前
汉堡包应助兔叽采纳,获得10
24秒前
桑榆发布了新的文献求助10
24秒前
乐观的涵柳完成签到 ,获得积分10
25秒前
zhuhan发布了新的文献求助10
26秒前
高分求助中
Sustainability in Tides Chemistry 2000
The ACS Guide to Scholarly Communication 2000
Studien zur Ideengeschichte der Gesetzgebung 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Threaded Harmony: A Sustainable Approach to Fashion 810
Pharmacogenomics: Applications to Patient Care, Third Edition 800
Ожившие листья и блуждающие цветы. Практическое руководство по содержанию богомолов [Alive leaves and wandering flowers. A practical guide for keeping praying mantises] 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3079106
求助须知:如何正确求助?哪些是违规求助? 2731711
关于积分的说明 7520183
捐赠科研通 2380546
什么是DOI,文献DOI怎么找? 1262296
科研通“疑难数据库(出版商)”最低求助积分说明 611848
版权声明 597396